Cargando…
Clinical validation of S100B use in management of mild head injury
BACKGROUND: Despite validated guidelines, management of mild head injury (MHI) is still associated with excessive computed tomography (CT) scanning. Reports concerning serum levels of S100B have shown promise concerning safe reduction in CT scanning but clinical validation and actual impact on patie...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527238/ https://www.ncbi.nlm.nih.gov/pubmed/23102492 http://dx.doi.org/10.1186/1471-227X-12-13 |
_version_ | 1782253681868013568 |
---|---|
author | Calcagnile, Olga Undén, Linda Undén, Johan |
author_facet | Calcagnile, Olga Undén, Linda Undén, Johan |
author_sort | Calcagnile, Olga |
collection | PubMed |
description | BACKGROUND: Despite validated guidelines, management of mild head injury (MHI) is still associated with excessive computed tomography (CT) scanning. Reports concerning serum levels of S100B have shown promise concerning safe reduction in CT scanning but clinical validation and actual impact on patient management is unclear. In 2007, S100B was introduced into emergency department (ED) clinical management routines in Halmstad, Sweden. MHI patients with low (<0.10 mikrogram/L) levels of S100B could be discharged without CT. Our aim was to examine the clinical impact and performance of S100B in clinical use for MHI patients. METHODS: Adult ([≥]18 years) patients with MHI (GCS 14–15, loss of consciousness and/or amnesia and no additional risk factors) and S100B sampling within 3 hours were prospectively included in this validation study. Patients were managed according to the adapted guidelines and management was documented. Outcome was determined with a questionnaire 3 months post-trauma and medical records to identify significant intracranial complications such as new neuroimaging, neurosurgery and/or death related to the trauma. RESULTS: 512 patients were included. 24 (4.7%) showed traumatic abnormalities on CT and 1 patient died (0.2%). 138 patients (27%) had normal S100B levels and 374 patients (73%) showed elevated S100B levels. No patients with a normal S100B level showed significant intracranial complication. 44 patients (32%) were managed with CT despite the guidelines recommending discharge (all these CT scans were normal) and 28 patients (7%) were discharged despite a CT recommendation (follow-up was normal in all these patients). S100B had a sensitivity of 100% (95% CI 83-100%) and a specificity of 28% (95% CI 24-33%) for significant intracranial complications. CONCLUSION: The clinical use of S100B within our existing guidelines for management of MHI is safe and effective. Adult MHI patients, without additional risk factors and with normal S100B levels within 3 hours of injury, can safely be discharged from the hospital. |
format | Online Article Text |
id | pubmed-3527238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35272382012-12-21 Clinical validation of S100B use in management of mild head injury Calcagnile, Olga Undén, Linda Undén, Johan BMC Emerg Med Research Article BACKGROUND: Despite validated guidelines, management of mild head injury (MHI) is still associated with excessive computed tomography (CT) scanning. Reports concerning serum levels of S100B have shown promise concerning safe reduction in CT scanning but clinical validation and actual impact on patient management is unclear. In 2007, S100B was introduced into emergency department (ED) clinical management routines in Halmstad, Sweden. MHI patients with low (<0.10 mikrogram/L) levels of S100B could be discharged without CT. Our aim was to examine the clinical impact and performance of S100B in clinical use for MHI patients. METHODS: Adult ([≥]18 years) patients with MHI (GCS 14–15, loss of consciousness and/or amnesia and no additional risk factors) and S100B sampling within 3 hours were prospectively included in this validation study. Patients were managed according to the adapted guidelines and management was documented. Outcome was determined with a questionnaire 3 months post-trauma and medical records to identify significant intracranial complications such as new neuroimaging, neurosurgery and/or death related to the trauma. RESULTS: 512 patients were included. 24 (4.7%) showed traumatic abnormalities on CT and 1 patient died (0.2%). 138 patients (27%) had normal S100B levels and 374 patients (73%) showed elevated S100B levels. No patients with a normal S100B level showed significant intracranial complication. 44 patients (32%) were managed with CT despite the guidelines recommending discharge (all these CT scans were normal) and 28 patients (7%) were discharged despite a CT recommendation (follow-up was normal in all these patients). S100B had a sensitivity of 100% (95% CI 83-100%) and a specificity of 28% (95% CI 24-33%) for significant intracranial complications. CONCLUSION: The clinical use of S100B within our existing guidelines for management of MHI is safe and effective. Adult MHI patients, without additional risk factors and with normal S100B levels within 3 hours of injury, can safely be discharged from the hospital. BioMed Central 2012-10-27 /pmc/articles/PMC3527238/ /pubmed/23102492 http://dx.doi.org/10.1186/1471-227X-12-13 Text en Copyright ©2012 Calcagnile et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Calcagnile, Olga Undén, Linda Undén, Johan Clinical validation of S100B use in management of mild head injury |
title | Clinical validation of S100B use in management of mild head injury |
title_full | Clinical validation of S100B use in management of mild head injury |
title_fullStr | Clinical validation of S100B use in management of mild head injury |
title_full_unstemmed | Clinical validation of S100B use in management of mild head injury |
title_short | Clinical validation of S100B use in management of mild head injury |
title_sort | clinical validation of s100b use in management of mild head injury |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527238/ https://www.ncbi.nlm.nih.gov/pubmed/23102492 http://dx.doi.org/10.1186/1471-227X-12-13 |
work_keys_str_mv | AT calcagnileolga clinicalvalidationofs100buseinmanagementofmildheadinjury AT undenlinda clinicalvalidationofs100buseinmanagementofmildheadinjury AT undenjohan clinicalvalidationofs100buseinmanagementofmildheadinjury |